LENZ Therapeutics (LENZ) Gains from Investment Securities (2020 - 2026)
LENZ Therapeutics (LENZ) reported Gains from Investment Securities of -$1000.0 for Q1 2026, up 99.7% on a QoQ basis from -$330000.0 in Q3 2024.
LENZ Therapeutics (LENZ) has 6 years of Gains from Investment Securities data on file, last reported at -$1000.0 in Q1 2026.
- Quarterly Gains from Investment Securities changed N/A year-over-year to -$1000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1000.0 (changed N/A YoY) and the FY2024 annual result came in at $1.0 million, down 67.52% from the prior year.
- Gains from Investment Securities climbed to -$1000.0 in Q1 2026 per LENZ's latest filing, from -$330000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $1.7 million in Q2 2023 and bottomed at -$330000.0 in Q3 2024.
- The 4-year median for Gains from Investment Securities is $30472.5 (2022), against an average of $267853.3.
- The widest annual swing landed in 2023, when Gains from Investment Securities surged 3748.37%; it then plunged 3283.18% in 2024.
- Tracing LENZ's Gains from Investment Securities over 4 years: stood at $139055.0 in 2022, then tumbled by 293.45% to -$269000.0 in 2023, then dropped by 22.68% to -$330000.0 in 2024, then jumped by 99.7% to -$1000.0 in 2026.
- Per Business Quant, the three latest LENZ Gains from Investment Securities figures stand at -$1000.0 (Q1 2026), -$330000.0 (Q3 2024), and $330000.0 (Q2 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | LENZ Therapeutics | 235.77 Mn | 235.77 Mn | 825,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,000.00 |
| Mar 31, 2026 | -1,000.00 |
| Sep 30, 2024 | -330,000.00 |
| Sep 30, 2024 | -330,000.00 |
| Jun 30, 2024 | 330,000.00 |
| Jun 30, 2024 | 330,000.00 |
| Mar 31, 2024 | 1.05 Mn |
| Mar 31, 2024 | 1.05 Mn |
| Dec 31, 2023 | -269,000.00 |
| Dec 31, 2023 | -269,000.00 |
| Sep 30, 2023 | 10,367.00 |
| Sep 30, 2023 | 10,367.00 |
| Jun 30, 2023 | 1.69 Mn |
| Jun 30, 2023 | 1.69 Mn |
| Dec 31, 2022 | 139,055.00 |
| Dec 31, 2022 | 139,055.00 |
| Sep 30, 2022 | 17,000.00 |
| Sep 30, 2022 | 17,000.00 |
| Jun 30, 2022 | 43,945.00 |
| Jun 30, 2022 | 43,945.00 |
| Dec 31, 2021 | 300,000.00 |
| Dec 31, 2021 | 300,000.00 |
| Jun 30, 2021 | 6,000.00 |
| Jun 30, 2021 | 6,000.00 |
| Mar 31, 2021 | 2.89 Mn |
| Mar 31, 2021 | 2.89 Mn |
| Dec 31, 2020 | 832,983.00 |
| Dec 31, 2020 | 832,983.00 |
| Sep 30, 2020 | 548,375.00 |
| Sep 30, 2020 | 548,375.00 |
| Jun 30, 2020 | 832,983.00 |
| Jun 30, 2020 | 832,983.00 |